The 12-month study will assess how a digital platform designed for asthma management impacts symptom control, medication adherence, and healthcare utilization in patients with moderate to severe asthma.
RT’s Three Key Takeaways:
- Study Focus: The 12-month study, conducted by Guy’s and St Thomas’ NHS Foundation Trust in collaboration with Aptar Digital Health and Lindus Health, aims to evaluate the impact of the ADH Respiratory DMP on asthma symptom control, medication adherence, and healthcare utilization in 118 adults with moderate to severe asthma.
- Platform Features: The ADH Respiratory DMP, which includes a mobile app connected to Aptar Digital Health’s HeroTracker Sense inhaler sensors, provides real-time tracking, medication reminders, and educational resources to improve asthma management and foster adherence.
- Adherence Importance: According to Professor David Jackson, improving adherence to inhaled corticosteroids through electronic monitoring could enhance asthma control and reduce unnecessary escalation to costly biologic agents.
Digital health solutions provider Aptar Digital Health announced a collaboration with Guy’s and St Thomas’ NHS Foundation Trust to evaluate the impact of its respiratory disease management platform, ADH Respiratory DMP, on asthma patients.
Both organizations are partnering with the clinical research organization Lindus Health to execute the study. The clinical study, which began in July and will run for 12 months, will recruit 118 adults with moderate to severe asthma, with the primary aim of assessing the improvement of asthma symptom control.
During the study, clinical data, including asthma control symptoms, quality of life, asthma controller medication adherence, healthcare resource utilization, and overall satisfaction with the digital solution, will be evaluated.
Respiratory Disease Management Platform
The ADH Respiratory DMP is designed to improve asthma symptom control, technique, and engagement. It includes a patient mobile application that connects to inhaler sensors, such as Aptar Digital Health’s HeroTracker Sense, and a software portal for healthcare professionals.
It aims to empower individuals by offering medication and symptom management with real-time tracking, reminders, and educational resources via a mobile app. By fostering behavior change and facilitating adherence, this digital platform aims to reduce asthma symptoms, rescue medication usage, exacerbations, and unnecessary healthcare visits.
[RELATED: Two-thirds of Patients Hospitalized for COPD Misuse Inhalers, Study Finds]
“Poor adherence to inhaled steroids remains the biggest barrier to asthma control. At the same time, a failure to identify and correct suboptimal adherence leads to unnecessary escalation to very costly biologic agents due to the incorrect assumption many patients have severe asthma when they do not,” says professor David Jackson, PhD, consultant in asthma and eosinophilic lung diseases at Guy’s and St Thomas’ NHS Foundation Trust and chief investigator of the clinical study, in a release. “As such, electronic monitoring of ICS (inhaled corticosteroids) adherence has enormous potential to both improve quality of care and reduce healthcare costs in asthma, and we are excited to start this study with the aim of demonstrating this.”
Photo caption: Aptar Digital Health’s patient mobile app and HeroTracker Sense sensor
Photo credit: Business Wire
